| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A biological classification of Huntington's disease: the Integrated Staging System
|
Tabrizi, Sarah J
|
|
|
21 |
7 |
p. 632-644
|
article
|
| 2 |
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA
|
Lynch, Holly Fernandez
|
|
|
21 |
7 |
p. 593-594
|
article
|
| 3 |
A cinematic exploration of technology and the brain
|
Kirby, Tony
|
|
|
21 |
7 |
p. 595-596
|
article
|
| 4 |
A new option for patients with treatment-resistant migraine
|
Ornello, Raffaele
|
|
|
21 |
7 |
p. 578-579
|
article
|
| 5 |
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials
|
Zipser, Carl M
|
|
|
21 |
7 |
p. 659-670
|
article
|
| 6 |
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
|
Foley, John F
|
|
|
21 |
7 |
p. 608-619
|
article
|
| 7 |
Correction to Lancet Neurol 2021; 20: 615–26
|
|
|
|
21 |
7 |
p. e7
|
article
|
| 8 |
Correction to Lancet Neurol 2021; 20: 917–29
|
|
|
|
21 |
7 |
p. e7
|
article
|
| 9 |
Correction to Lancet Neurol 2022; 21: 417–27
|
|
|
|
21 |
7 |
p. e7
|
article
|
| 10 |
Correction to Lancet Neurol 2022; 21: 620–31
|
|
|
|
21 |
7 |
p. e7
|
article
|
| 11 |
Epilepsy syndromes: an essential piece of the puzzle
|
The Lancet Neurology,
|
|
|
21 |
7 |
p. 577
|
article
|
| 12 |
Huntington's disease: disappointments and new beginnings
|
Saft, Carsten
|
|
|
21 |
7 |
p. 582-584
|
article
|
| 13 |
Imaging of the carotid artery
|
Evans, Nicholas R
|
|
|
21 |
7 |
p. 588
|
article
|
| 14 |
Imaging of the carotid artery – Authors' reply
|
Brown, Martin M
|
|
|
21 |
7 |
p. 588-589
|
article
|
| 15 |
Major advances in neuromuscular disorders in the past two decades
|
Wadman, Renske I
|
|
|
21 |
7 |
p. 585-587
|
article
|
| 16 |
Medieval treatment of epilepsy in England
|
Mohammed, Hamzah
|
|
|
21 |
7 |
p. 592
|
article
|
| 17 |
Natalizumab for multiple sclerosis: the dilemma of NOVA
|
Hellwig, Kerstin
|
|
|
21 |
7 |
p. 579-581
|
article
|
| 18 |
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities
|
Tabrizi, Sarah J
|
|
|
21 |
7 |
p. 645-658
|
article
|
| 19 |
Reasons to be glad
|
West, Leah
|
|
|
21 |
7 |
p. 596
|
article
|
| 20 |
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
|
Ashina, Messoud
|
|
|
21 |
7 |
p. 597-607
|
article
|
| 21 |
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study
|
van Essen, Thomas A
|
|
|
21 |
7 |
p. 620-631
|
article
|
| 22 |
Tanuja Chitnis: on role models, family, and multiple sclerosis
|
Burton, Adrian
|
|
|
21 |
7 |
p. 591
|
article
|
| 23 |
The Mobile Toolbox for monitoring cognitive function
|
Gershon, Richard C
|
|
|
21 |
7 |
p. 589-590
|
article
|
| 24 |
Tina Charway-Felli
|
|
|
|
21 |
7 |
p. 592
|
article
|
| 25 |
Treatment decision making in acute subdural haematoma
|
Brennan, Paul M
|
|
|
21 |
7 |
p. 581-582
|
article
|
Journal description